ClinicalTrials.gg
Status unknownNCT00294476Updated Oct 12, 2006

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

A Phase 2 interventional study of IVIG and Biological Therapy in Cancer of Colon, Malignant Melanoma and Urologic Cancer, sponsored by GammaCan. Status unknown at 3 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-10-12.

Sponsored by GammaCan · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2006), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 40 studies in Colonic Neoplasms with a site in Israel — 5 open to participants now, 6 under way, 2 of them phase 3. Colonic Neoplasms · Israel.

Enrollment
26th of 31
30 · median 122
Started
2005
the only one that year
Phase 2
6 of 40
none open now
Registered
4th of 40
by date

Among the 40 studies in Colonic Neoplasms with a site in Israel, this one is the 26th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2005, is one of 6 in phase 2, and was the 4th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

5 of the 40 studies in Colonic Neoplasms with a site in Israel are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Colonic Neoplasms with a site in Israel, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of IVIG in the treatment of metastatic cancer of the prostate, colon and melanoma.

Read the detailed description

This study is a one arm, open label, multi-center, phase II study. Its aim is to evaluate the safety and efficacy of IVIG administered as treatment for metastasis solid tumors. IVIG was proven as affecting the growth of tumor metastasis in animals' models.

Study population is including male or female, 18 and older, diagnosed as having a primary tumor (colon, melanoma or prostate) with measurable metastasis (according to the RECIST criteria) in soft tissues and/ or tumor markers in prostate cancer, for which there is no better alternate treatment.

The patients receive the IVIG calculated as 1g/kg/bodyweight per cycle (defined as every 21 days) until progression disease is noted. All patients are being followed for a period of 6 months after patient's withdrawal.

03

Conditions studied

  • Cancer of Colon
  • Malignant Melanoma
  • Urologic Cancer

Keywords

  • IVIg
  • Cancer
  • Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than 18 years of age.
  • Histological confirmed diagnosis of a prostate adenocarcinoma, melanoma or colon cancer
  • At least one measurable site of disease as evidenced by CT or MRI, criteria in soft tissue OR lymph nodes and OR tumor markers as appropriate
  • Rising PSA in 3 consecutive weeks taken at least one week apart with a value of at least 5 ng/mL
  • Testosterone that is less than 50 ng/dL in prostate patients
  • Prostate cancer patients receiving radiation therapy that is less than 30% of pelvic/total bone mass and where acute radiation toxicity is resolved
  • Performance status 0- 2
  • WBC > 1,500 cells/mm3, > 9 g/dL, and > 100,000 cells/mm3 and \< 500,000 cells/mm3
  • Adequate renal function: serum creatinine \< 2.0 mg/dL, or CCT>= 50 ml/min
  • of at least 3 months
  • Willing to participate in a 6 month follow-up
  • Female patients of must have negative pregnancy test within 7 days before initiation of study drug dosing. Post menopausal women must be amenorrheic for at least 12 months to be considered of non- childbearing potential. Male and female patients of must agree to employ an effective barrier method of throughout the study and for up to 3 months following discontinuation of study drug.
  • Patients who have given written

Exclusion criteria

Exclusion Criteria:

  • Patients suffering from primary or brain or spinal tumor.
  • Patients with known sensitivity to any of the components of the IVIG formulation .
  • IgA levels \<=60mg/dl .
  • Treatment with IVIG 6 months prior to study start
  • Patients that are with known seropositivity for or with a known diagnosis of human immunodeficiency virus (HIV) infection. (AIDS)
  • Patients with significant diseases, active infection or uncontrolled medical condition (e.g., pulmonary, neurological, cardiovascular, gastrointestinal, genitourinary) considered high risk for new drug treatment/ who in the opinion of the investigator would be excluded from the study
  • Female patients who are pregnant or breast-feeding.
  • Patient has a severe and/or uncontrolled renal failure.
  • Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
  • Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable and who in the opinion of investigator, are unlikely to comply with the study protocol
  • Patients who are currently participating or have participated in another clinical trial in the last 30 days.
  • Patients who have undergone chemotherapy in the last 4 weeks
  • Patients who are being treated with antibiotic treatment for an active infection
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants

Interventions

06

What researchers measure

Primary outcomes

  1. 1. Tumor response is measured at baseline and evaluated every 3 treatment cycles (9 weeks) by RECIST(CT or MRI measurements), Time to Progression

  2. and Serum tumor markers as appropriate CEA, PSA. Additionally, ECOG performance status is evaluated before each treatment cycle

Secondary outcomes

  1. Secondary efficacy measurements: Overall survival, Karnofsky Performance Status is evaluated at baseline and before each treatment cycle and Quality of life questionnaires is completed and evaluated at baseline and every 3 treatment cycles (9 weeks)

  2. Safety assessments include Adverse events and laboratory values which are measured and evaluated before every treatment cycle

07

Study locations

3 of 3 sites recruiting
  • Ella Institute, Oncology institute, Sheba Medical Center
    Tel Hashomer, Ramat Gan 52621, Israel
    Recruiting
    • Jacob Schachter, M.D · Contact972-3-5302243
    • Dov Barak, R.N. · Contact972-3-5305201
    • Jacob Schachter, M.D. · Principal investigator
  • Oncology Institute, Sheba Medical Center
    Tel Hashomer, Ramat Gan 52621, Israel
    Recruiting
    • Dan Aderka · Contact972-3-5305259
    • Dov Barak, R.N. · Contact972-3-5305201
    • Dan Aderka, M.D · Principal investigator
  • Oncology institute, Shaare Zedek Medical Center
    Jerusalem, Israel
    Recruiting
    • Alberto Gabison, M.D. · Contact972-2-6555036
    • Rama Sapir, M.Sc. · Contact972-2-6555727
    • Alberto Gabison, M.D. · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 12, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00294476
Lead sponsor
GammaCan
First posted
Feb 22, 2006
Start date
Jul 2005
Last update
Oct 12, 2006

Study contacts

Dan Aderka, M.D.
principal investigator · Oncology institute, Sheba Madical Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion